Claims
- 1. An isolated, synthetic or recombinant peptide of a minor Histocompatability antigen HA-1 origin, the isolated, synthetic or recombinant peptide comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X is histidine or arginine.
- 2. The isolated, synthetic or recombinant peptide of claim 1, wherein X is histidine.
- 3. The isolated, synthetic or recombinant peptide of claim 1, wherein the isolated, synthetic or recombinant peptide has a length of about 7 to 15 amino acids.
- 4. A vaccine comprising the isolated, synthetic or recombinant peptide of claim 1.
- 5. A composition comprising the isolated, synthetic or recombinant peptide of claim 1.
- 6. A process of inducing tolerance for transplants to reduce the rejection and/or Graft versus Host disease or to treat autoimmune disease in a subject, the process comprising:
administering the isolated, synthetic or recombinant peptide of claim 1 to a subject.
- 7. The process according to claim 6, wherein the isolated, synthetic or recombinant peptide is administered orally, intravenously, intraoccularly, intranasally, or combinations of any thereof.
- 8. A process for the elimination of hematopoietic cells presenting a peptide of an HLA class 1 origin, the process comprising:
inducing cytotoxic T-cells with the isolated, synthetic or recombinant peptide of claim 1; and placing the induced cytotoxic T-cells in contact with hematopoietic cells presenting the peptide of the HLA class 1 origin.
- 9. An analog of the isolated, synthetic or recombinant peptide of claim 1, wherein the analog is an antagonist for the activity of T cells recognizing the isolated, synthetic or recombinant peptide.
- 10. A process for producing antibodies, T-cell receptors, anti-idiotypic B-cells or T-cells, the process comprising:
administering the isolated, synthetic or recombinant peptide of claim 1 to a mammal, thus inducing production of the antibodies, T-cell receptors, anti-idiotypic B-cells or T-cells.
- 11. Antibodies, T-cell receptors, B-cells or T-cells produced by the process according to claim 10.
- 12. A process for producing a cytotoxic T-cell against a minor antigen, the process comprising:
providing an isolated, synthetic or recombinant peptide comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X represents histidine or arginine; and contacting a hematopoietic cell with the isolated, synthetic or recombinant peptide, thus, producing the cytotoxic T-cell.
- 13. The process according to claim 12, wherein the hematopoietic cell is negative for the minor antigen.
- 14. The process according to claim 12, wherein the minor antigen is HA-1.
- 15. The process according to claim 12, wherein contacting the hematopoietic cell with the isolated, synthetic or recombinant peptide is carried out ex vivo.
- 16. The process according to claim 12, further comprising transducing the cytotoxic T-cell with a suicide gene.
- 17. The process according to claim 12, wherein the cytotoxic T-cell is immortalized.
- 18. The process according to claim 12, wherein the cytotoxic T-cell is capable of expansion.
- 19. A cytotoxic T-cell, produced by the process according to claim 12.
- 20. The process according to claim 12, wherein the isolated, synthetic or recombinant peptide is about 7 to 15 amino acids in length.
- 21. An immunogenic polypeptide of a minor Histocompatability antigen HA-1 origin, comprising the sequence VLXDDLLEA (SEQ ID NO: 1) or an epitope thereof capable of producing an immune response, wherein X is histidine or arginine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
97202303.0 |
Jul 1997 |
EP |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/489,760, which is hereby incorporated herein in its entirety by this reference, filed Jan. 21, 2000, pending, which itself claims priority as a continuation of International Application No. PCT/NL98/00424, filed on Jul. 23, 1998, designating the United States of America, which itself claims priority from EP 97202303.0 filed on Jul. 23, 1997.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09489760 |
Jan 2000 |
US |
Child |
10791217 |
Mar 2004 |
US |
Parent |
PCT/NL98/00424 |
Jul 1998 |
US |
Child |
09489760 |
Jan 2000 |
US |